New York State Common Retirement Fund Boosts Holdings in Tempus AI, Inc. $TEM

New York State Common Retirement Fund raised its position in shares of Tempus AI, Inc. (NASDAQ:TEM) by 38.8% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 45,800 shares of the company’s stock after acquiring an additional 12,800 shares during the period. New York State Common Retirement Fund’s holdings in Tempus AI were worth $3,697,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. AQR Capital Management LLC bought a new position in Tempus AI during the 2nd quarter valued at about $54,020,000. Geode Capital Management LLC boosted its position in shares of Tempus AI by 411.4% during the second quarter. Geode Capital Management LLC now owns 649,420 shares of the company’s stock valued at $41,264,000 after buying an additional 522,443 shares during the period. Marex Group plc bought a new position in shares of Tempus AI during the second quarter valued at approximately $26,620,000. Gilder Gagnon Howe & Co. LLC raised its holdings in shares of Tempus AI by 1,747.6% in the second quarter. Gilder Gagnon Howe & Co. LLC now owns 413,081 shares of the company’s stock worth $26,247,000 after buying an additional 390,723 shares during the period. Finally, Patient Capital Management LLC bought a new stake in shares of Tempus AI during the 2nd quarter worth approximately $24,693,000. Institutional investors own 24.22% of the company’s stock.

Tempus AI Trading Up 4.7%

NASDAQ:TEM opened at $54.91 on Friday. The firm has a 50-day simple moving average of $66.36 and a 200-day simple moving average of $73.84. Tempus AI, Inc. has a one year low of $36.22 and a one year high of $104.32. The firm has a market cap of $9.77 billion, a P/E ratio of -46.14 and a beta of 5.22. The company has a debt-to-equity ratio of 2.45, a quick ratio of 3.12 and a current ratio of 3.28.

Wall Street Analysts Forecast Growth

TEM has been the topic of several research analyst reports. BTIG Research upped their price objective on Tempus AI from $96.00 to $105.00 and gave the company a “buy” rating in a research report on Tuesday, November 25th. Canaccord Genuity Group cut their price target on shares of Tempus AI from $95.00 to $80.00 and set a “buy” rating on the stock in a report on Monday, December 22nd. TD Cowen cut shares of Tempus AI from a “buy” rating to a “hold” rating in a research report on Tuesday, October 21st. Morgan Stanley raised their target price on shares of Tempus AI from $80.00 to $85.00 and gave the stock an “overweight” rating in a research report on Monday, December 1st. Finally, Piper Sandler decreased their price target on shares of Tempus AI from $105.00 to $80.00 and set a “neutral” rating for the company in a research note on Tuesday, November 11th. Six research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Tempus AI currently has a consensus rating of “Hold” and an average target price of $87.20.

Insider Buying and Selling at Tempus AI

In other Tempus AI news, CEO Eric P. Lefkofsky sold 166,250 shares of the company’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $74.10, for a total transaction of $12,319,125.00. Following the completion of the sale, the chief executive officer owned 9,008,033 shares in the company, valued at $667,495,245.30. This represents a 1.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO James William Rogers sold 19,966 shares of the stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $73.20, for a total value of $1,461,511.20. Following the sale, the chief financial officer directly owned 111,250 shares in the company, valued at $8,143,500. This trade represents a 15.22% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 761,582 shares of company stock worth $51,997,831. 26.27% of the stock is currently owned by corporate insiders.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.